Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells

Fuchs, 2002, Pretreatment prognostic factors and treatment results in children with hepatoblastoma: A report from the German Cooperative Pediatric Liver Tumor Study HB 94, Cancer, 95, 172, 10.1002/cncr.10632

Perilongo, 2004, Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2, Eur J Cancer, 40, 411, 10.1016/j.ejca.2003.06.003

Perilongo, 2009, Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma, N Engl J Med, 361, 1662, 10.1056/NEJMoa0810613

Warmann, 2009, Emerging gene-directed anti-tumor strategies against human hepatoblastoma, Expert Opin Biol Ther, 9, 1155, 10.1517/14712590903136696

Hoti, 2008, Liver transplantation for primary and metastatic liver cancers, Transpl Int, 21, 1107, 10.1111/j.1432-2277.2008.00735.x

Malogolowkin, 2000, Feasibility and toxicity of chemoembolization for children with liver tumors, J Clin Oncol, 18, 1279, 10.1200/JCO.2000.18.6.1279

Warmann, 2009, Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro, Pediatr Blood Cancer, 53, 145, 10.1002/pbc.21956

Hartmann, 2009, Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival, Clin Cancer Res, 15, 4538, 10.1158/1078-0432.CCR-08-2878

Stejskalova, 2009, Cytogenetic and array comparative genomic hybridization analysis of a series of hepatoblastomas, Cancer Genet Cytogenet, 194, 82, 10.1016/j.cancergencyto.2009.06.001

Humeniuk, 2009, Molecular targets for epigenetic therapy of cancer, Curr Pharm Biotechnol, 10, 161, 10.2174/138920109787315123

McConkey, 2008, Mechanisms of proteasome inhibitor action and resistance in cancer, Drug Resist Update, 11, 164, 10.1016/j.drup.2008.08.002

Marin, 2009, Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours, Curr Mol Med, 9, 1108, 10.2174/156652409789839125

Kang, 2009, Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy, Clin Cancer Res, 15, 1126, 10.1158/1078-0432.CCR-08-0144

Chonghaile, 2008, Mimicking the BH3 domain to kill cancer cells, Oncogene, 27, S149, 10.1038/onc.2009.52

High, 2010, The BH3-mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs, Mol Pharmacol, 77, 483, 10.1124/mol.109.060780

Shoemaker, 2006, A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo, Cancer Res, 66, 8731, 10.1158/0008-5472.CAN-06-0367

Adesina, 2009, Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways, Hum Pathol, 40, 843, 10.1016/j.humpath.2008.10.022

Warmann, 2008, Bcl-2 gene silencing in pediatric epithelial liver tumors, J Surg Res, 144, 43, 10.1016/j.jss.2007.03.054

Pietsch, 1996, Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma, Lab Invest, 74, 809

Doi, 1976, Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma, GANN, 67, 1

Berenbaum, 1981, Criteria for analyzing interactions between biologically active agents, Adv Cancer Res, 35, 269, 10.1016/S0065-230X(08)60912-4

Groninger, 2004, Pharmacokinetic studies in children with cancer, Crit Rev Oncol Hematol, 52, 173, 10.1016/j.critrevonc.2004.08.007

Oue, 2009, Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies, J Pediatr Surg, 44, 377, 10.1016/j.jpedsurg.2008.10.088

Warmann, 2005, Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma, Pediatr Hematol Oncol, 22, 373, 10.1080/08880010590964192

Letai, 2002, Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics, Cancer Cell, 2, 183, 10.1016/S1535-6108(02)00127-7

Kirkin, 2004, The role of Bcl-2 family members in tumorigenesis, Biochim Biophys Acta, 1644, 229, 10.1016/j.bbamcr.2003.08.009

Milella, 2004, Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells, Clin Cancer Res, 10, 7747, 10.1158/1078-0432.CCR-04-0908

Yamanaka, 2005, A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells, Mol Cancer Ther, 4, 1689, 10.1158/1535-7163.MCT-05-0064

Ocker, 2005, Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer, Gut, 54, 1298, 10.1136/gut.2004.056192

Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579

Ackler, 2008, ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo, Mol Cancer Ther, 7, 3265, 10.1158/1535-7163.MCT-08-0268

Chauhan, 2007, A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma, Oncogene, 26, 2374, 10.1038/sj.onc.1210028

Lock, 2008, Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program, Pediatr Blood Cancer, 50, 1181, 10.1002/pbc.21433

Fuchs, 1999, Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: A report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94, Klin Padiatr, 211, 305, 10.1055/s-2008-1043805

Malogolowkin, 2008, Redefining the role of doxorubicin for the treatment of children with hepatoblastoma, J Clin Oncol, 26, 2379, 10.1200/JCO.2006.09.7204